Select a medication above to begin.
Jevtana
cabazitaxel
Black Box Warnings .
Neutropenia
neutropenic deaths reported; monitor CBC frequently; do not admin. if ANC <1500 cells/mm^3; primary prophylaxis w/ G-CSF recommended in pts w/ high-risk clinical features, incl. older pts, poor performance status, hx of febrile neutropenia, extensive prior XRT ports, poor nutritional status, or other serious comorbidities; consider primary prophylaxis w/ G-CSF in all pts receiving 25 mg/m^2 dose
Severe Hypersensitivity Rxn
may incl. generalized rash/erythema, hypotension, bronchospasm; pts should receive premed; immediately D/C infusion, admin. appropriate tx if severe hypersensitivity rxns occur; contraindicated if severe hypersensitivity rxn hx to cabazitaxel or other drugs formulated w/ polysorbate 80
Adult Dosing .
Dosage forms: INJ
Special Note
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing incl. toxicity-related dose adjustments
prostate CA, metastatic castration-resistant
- [20 mg/m^2/dose IV x1 on day 1 of 21-day cycle]
- Max: 25 mg/m^2/dose; Info: use w/ prednisone 10 mg PO qd
renal dosing
- [see below]
- CrCl >15: no adjustment; CrCl <15: not defined, caution advised
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin 1.1-1.5x ULN or AST >1.5x ULN: 20 mg/m^2/dose x1 on day 1 of 21-day cycle; bilirubin 1.6-3x ULN: 15 mg/m^2/dose x1 on day 1 of 21-day cycle; bilirubin >3x ULN: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.